Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride

Background Introduction

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride is a specialized E3 ligase ligand-linker conjugate used extensively in the development of PROTACs (Proteolysis Targeting Chimeras). This compound combines a thalidomide-based cereblon (CRBN) E3 ligase ligand with a polyethylene glycol (PEG4) and C2 amide-linked spacer, terminated with a primary amine. Such structures enable the design of PROTACs for selective protein degradation, a powerful modality in chemical biology and drug discovery.

Mechanism

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride functions by recruiting the CRBN E3 ubiquitin ligase complex, thanks to the thalidomide moiety. The PEG4-C2 amide linker provides spatial flexibility and solubility, while the terminal amine group allows for facile conjugation to various ligands targeting specific proteins of interest. When incorporated into a PROTAC, the molecule acts as a molecular bridge: one end binds the CRBN E3 ligase and the other, via chemical conjugation, binds a target protein ligand. This proximity leads to the target protein's ubiquitination and subsequent proteasomal degradation.

Applications

This E3 ligase ligand-linker conjugate is widely used for synthesizing cereblon-based PROTACs and molecular glues. Its applications include the development of tool compounds for chemical biology, creation of targeted protein degradation therapeutics for diseases such as cancer or neurodegeneration, and structure-activity relationship (SAR) studies for optimizing PROTAC design. Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride serves as a versatile building block to accelerate research in targeted protein degradation.

• PEG4 linker improves water solubility and pharmacokinetic properties for superior PROTAC performance
• Terminal amine group enables flexible conjugation to diverse target ligands for efficient CRBN-based PROTAC development

Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by bridging E3 ligases with specific protein targets. The following provides a detailed description of this molecule, focusing on its linker, ligand, and the selection of compatible target protein ligands.

Linker: This molecule features a PEG4 linker, known for its optimal length and flexibility, which enhances solubility and facilitates effective spatial arrangement. The linker is non-cleavable, providing stability and ensuring sustained interaction between the E3 ligase and the target protein.

Ligand: The ligand component of this conjugate is derived from thalidomide, a well-characterized immunomodulatory compound. It exhibits a phthalimide moiety, which is crucial for binding to the cereblon E3 ubiquitin ligase, thus directing the PROTAC to its intended degradation pathway.

Reactive Site: The reactive site features an amine group, which is well-suited for coupling with carboxylic acid or activated ester groups on target protein ligands. Recommended reaction types include amide bond formation, which provides robust and stable conjugation.

Recommended Target Protein Ligand: The ideal warhead for this molecule is a small-molecule inhibitor with a carboxyl functional group, allowing for efficient coupling with the amine on the linker. This configuration maximizes the degradation efficiency of proteins involved in disease pathways, offering a strategic advantage in research focused on elucidating protein function and therapeutic target validation.